Mill Creek Life Sciences — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Mill Creek Life Sciences is a private, commercial-stage company providing essential raw materials for the cell therapy industry. Its primary business is the manufacturing and sale of cGMP-grade human platelet lysates (PLTMax®, PLTGold®), which are used as growth media supplements in over 50 clinical trials globally. The company leverages its deep clinical experience and a licensed dendritic cell vaccine technology to support partners in developing advanced cellular therapies. With a foundation in Mayo Clinic research, MCLS operates as a key enabler in the translational medicine ecosystem.

OncologyRegenerative Medicine

Technology Platform

Proprietary manufacturing platform for human platelet lysates (hPL), derived from human platelets, used as xeno-free, clinical-grade cell culture supplements. Also holds a license for a dendritic cell vaccine platform combining allogeneic tumor lysates with autologous dendritic cells.

Opportunities

The rapid growth in cell and gene therapy clinical trials and approved products drives increasing demand for high-quality, xeno-free cell culture supplements like hPL.

Regulatory pressure to move away from animal sera provides a strong tailwind for adoption.

The licensed DC vaccine platform represents a potential high-value therapeutic asset in the high-need glioblastoma market.

Risk Factors

Revenue is concentrated on the hPL product line, making it vulnerable to market shifts towards synthetic alternatives or new technologies.

The supply of human platelet raw material is subject to donor-dependent volatility.

The internal DC vaccine program is at an early, high-risk stage of development with significant technical and clinical hurdles.

Competitive Landscape

MCLS competes in the cell culture supplements market against large life science tools companies (e.g., Thermo Fisher, Merck) offering serum-free media and against other specialized hPL producers. Its key competitive advantages are its first-mover status, extensive clinical trial validation history, and specific cGMP manufacturing expertise. In the DC vaccine space, it would face competition from other immunotherapy approaches for GBM.

More companies in Cell & Gene Therapy →More companies in United States →